Sinovac doubles COVID-19 vaccine production capacity

Published On 2021-04-02 11:58 GMT   |   Update On 2021-04-02 11:58 GMT

Beijing: Chinese biopharmaceutical firm Sinovac said Friday a third production line for its Covid-19 vaccine has been put into use, doubling its annual capacity of the jabs to two billion doses.Its CoronaVac is one of four domestic vaccines given conditional approval by Chinese authorities, which helps rush emergency drugs to market.On Wednesday, experts from the World Health Organization said...

Login or Register to read the full article

Beijing: Chinese biopharmaceutical firm Sinovac said Friday a third production line for its Covid-19 vaccine has been put into use, doubling its annual capacity of the jabs to two billion doses.

Its CoronaVac is one of four domestic vaccines given conditional approval by Chinese authorities, which helps rush emergency drugs to market.
On Wednesday, experts from the World Health Organization said an interim analysis of clinical trial data from two Chinese vaccines, including Sinovac's product, showed they demonstrated "safety and good efficacy", although more data is still needed.
"Over 200 million doses of CoronaVac have been delivered to over 20 countries, including China," said Sinovac in its latest statement.
Although Sinovac's jab has been approved by domestic regulators, it has yet to receive authorisation by what the WHO considers "a stringent regulatory authority", noted the UN health agency's Strategic Advisory Group of Experts on Immunization (SAGE).
Sinovac is among Chinese firms to have submitted data in applications for the WHO's emergency use listing, which opens the door for the jabs to join the global Covax programme, which aims to ensure equitable access to Covid-19 vaccinations.


Tags:    
Article Source : AFP

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News